期刊文献+

西多福韦对HeLa细胞增殖抑制作用的研究 被引量:1

Anti-proliferative effect of cidofovir on HeLa cells
下载PDF
导出
摘要 目的研究抗病毒药西多福韦(CDV)对HeLa细胞的增殖抑制作用。方法采用MTT法分析CDV和阳性对照药顺铂(DDP)对HeLa细胞增殖活力的影响;利用细胞集落形成实验和Giemsa染色技术,观察CDV和DDP导致HeLa细胞凋亡情况;利用流式细胞仪观察CDV和DDP对细胞凋亡及细胞周期影响。结果 MTT法和细胞集落实验结果显示CDV能明显抑制HeLa细胞的增殖活性;流式细胞仪测定显示CDV和DDP使HeLa细胞阻滞于细胞周期的S期,并诱导HeLa细胞发生凋亡。结论 CDV对HeLa细胞具有明显的增殖抑制作用,并能诱导细胞凋亡,CDV有可能成为宫颈癌治疗的另一策略。 Objective To study the inhibition of cidofovir(CDV)on proliferation of HeLa cells.Methods MTT assay was used to analyze the influence of CDV and cisplatin(D D P)on HeLa cell proliferation.Clone formation assay and Giemsa staining were used to observe the situation of cell apoptosis caused by CDV and DDP on HeLa cells.Flow cytometry was used to detect the shape and size of apoptotic cells after PI staining.Results CDV could inhibit the proliferation of HeLa cells.Results of flow cytometry assay showed that CDV induced cells arrested in S-phase and cell apoptosis.Conclusion CDV can inhibit HeLa cells proliferation,regulate cell cycle and trigger apoptosis,which makes it become another potential treatment strategy of cervical cancer.
作者 吴五洲 徐祥 欧琴 李蓓 丁娜娜 李明远 杨靖 WU Wuzhou;XU Xiang;0U Qin;LI Bei;DING Nana;LI Mingyuan;YANG Jing(Taihe Hospital, Hubei University of Medicine, Shiy an, Hubei 442000 , China;Department of Microbiology Hubei University of Medicine y Shiyan y Hubei 442000 , China;Department of Microbiology, West China School of Preclinical and Forensic Medicine, Sichuan University,Chengdu ,Sichuan 610041, China)
出处 《安徽医药》 CAS 2017年第8期1494-1497,共4页 Anhui Medical and Pharmaceutical Journal
基金 湖北省教育厅科学研究计划项目(B2016113) 十堰市科技局市级科学技术研究与开发专项基金项目(16K70) 湖北医药学院研究生启动金资助计划项目(2015QDJZR08) 2015年湖北省省级大学生创新创业训练计划项目(201510929024)
关键词 人乳头瘤病毒 HELA细胞 西多福韦 顺钼 细胞凋亡 Human papillomavirus HeLa cell Cidofovir Cisplatin Apoptosis
  • 相关文献

参考文献10

二级参考文献131

  • 1吴剑波,郑家润.西多福韦的药理、毒理及其在皮肤科的应用[J].国外医学(皮肤性病学分册),2005,31(1):3-5. 被引量:4
  • 2柳友清,邢辉,韩晓兵,石小艳,梁缝奇,陈刚,马丁.顺铂诱导宫颈癌Hela细胞凋亡及其作用机制的研究[J].中国肿瘤临床,2006,33(1):1-4. 被引量:26
  • 3常青,秦仁义,高军,冯延平,黄涛.反义缺氧诱导因子-1α对胰腺癌细胞BxPC-3化疗敏感性的影响[J].中国普通外科杂志,2006,15(6):423-427. 被引量:7
  • 4Baalbergen A, Smedts F, Ewing P, et al. HPV-type has no impact on survival of patients with adenocarcinoma of the uterine cervix [ J]. Gynecologic Oncology,2013,128 (3) :530 - 534.
  • 5Kenny SL, Mc Bride HA, Jamison J, et al. Mesonephric adenocarci- nomas of the uterine cervix and corpus : HPV-negative neoplasms that are commonly PAX8, CA125, and HMGA2 positive and that may be immunoreactive with T1T1 and hepatocyte nuclear factor 1 - β[J]. Am J Surg Pathol,2012,36(6) :799 -807.
  • 6Siriaunkgul S, Utaipat U, Suthipintawong C, et al. HPV genotyping in adenocarcinoma of the uterine cervix in Thailand [ J ]. Int J Gynaecol Obstet,2013,123 (3) :226 - 230.
  • 7Crow JM. HPV: The global burden. Nature, 2012,488(7413):S2-S3.
  • 8Snoeck R. Papillomavirus and treatment. Antiviral Res, 2006, 71(2-3):181-191.
  • 9Bernard HU. Established and potential strategies againstpapillomavirus infections. J Antimicrob Chemother, 2004, 53(2):137-139.
  • 10De Clercq E, Holy A. Acyclic nucleoside phosphonates: a key class ofantiviral drugs. Nat Rev Drug Discov, 2005,4(11):928-940.

共引文献45

同被引文献57

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部